Drug
Fremanezumab
Fremanezumab: highest development phase Post-Market, developed by Teva. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Teva
Trials
| Drug | Phase | Indication |
|---|---|---|
| Fremanezumab NCT06173661 | Post-Market | Migraine |
| Fremanezumab NCT02621931 | Phase 3 | Migraine |
| Fremanezumab NCT04530110 | Phase 3 | Migraine |
Latest
No recent events.
Follow Fremanezumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.